Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Keating

Showing results (981-990 of 1,115) with videos related to

Pageof 112
Sort By:
Leukemia Research|November 26, 2008
Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME geneShelly R Gunn, Aswani R Bolla, Lynn L Barron, et al.
Cancer|February 28, 2006
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemiaDeborah A Thomas, Stefan Faderl, Susan O'Brien, et al.
Blood|June 26, 2008
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemiaLaura Z Rassenti, Sonia Jain, Michael J Keating, et al.
Blood|February 25, 2006
Eradication of minimal residual disease in hairy cell leukemiaFarhad Ravandi, Jeffrey L Jorgensen, Susan M O'Brien, et al.
Leukemia|May 18, 2018
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategiesPhilip A Thompson, Christine B Peterson, Paolo Strati, et al.
Kidney International|May 27, 2020
Genome-wide non-HLA donor-recipient genetic differences influence renal allograft survival via early allograft fibrosisZhongyang Zhang, Madhav C Menon, Weijia Zhang, et al.
Blood|October 11, 2003
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylateDeborah A Thomas, Stefan Faderl, Jorge Cortes, et al.
BMC Medical Genetics|February 16, 2017
Genetic analysis of impaired trimethylamine metabolism using whole exome sequencingYiran Guo, Liang-Dar Hwang, Jiankang Li, et al.
The Lancet. Oncology|October 5, 2019
Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort studyCarmen D Herling, Kevin R Coombes, Axel Benner, et al.
Frontiers in Genetics|April 12, 2014
Return of results in the genomic medicine projects of the eMERGE networkIftikhar J Kullo, Ra'ad Haddad, Cynthia A Prows, et al.
Pageof 112

Showing results (981-990 of 1,115) with videos related to

Sort By:
Pageof 112
Leukemia Research|November 26, 2008
Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME geneShelly R Gunn, Aswani R Bolla, Lynn L Barron, et al.
Cancer|February 28, 2006
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemiaDeborah A Thomas, Stefan Faderl, Susan O'Brien, et al.
Blood|June 26, 2008
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemiaLaura Z Rassenti, Sonia Jain, Michael J Keating, et al.
Blood|February 25, 2006
Eradication of minimal residual disease in hairy cell leukemiaFarhad Ravandi, Jeffrey L Jorgensen, Susan M O'Brien, et al.
Leukemia|May 18, 2018
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategiesPhilip A Thompson, Christine B Peterson, Paolo Strati, et al.
Kidney International|May 27, 2020
Genome-wide non-HLA donor-recipient genetic differences influence renal allograft survival via early allograft fibrosisZhongyang Zhang, Madhav C Menon, Weijia Zhang, et al.
Blood|October 11, 2003
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylateDeborah A Thomas, Stefan Faderl, Jorge Cortes, et al.
BMC Medical Genetics|February 16, 2017
Genetic analysis of impaired trimethylamine metabolism using whole exome sequencingYiran Guo, Liang-Dar Hwang, Jiankang Li, et al.
The Lancet. Oncology|October 5, 2019
Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort studyCarmen D Herling, Kevin R Coombes, Axel Benner, et al.
Frontiers in Genetics|April 12, 2014
Return of results in the genomic medicine projects of the eMERGE networkIftikhar J Kullo, Ra'ad Haddad, Cynthia A Prows, et al.
Pageof 112